We are initially focused on discovering therapeutics for alcoholic and non-alcoholic fatty liver diseases.
Using AI and metabolomic data from liver biopsies and biofluids of patients with fatty liver diseases, we are discovering molecular mechanisms leading to dysregulation of biofluid metabolites, as well as drug candidates targeting these mechanisms.
